Sleep Disorders Unit, Department of Thoracic Medicine, Medical School, University of Crete, Heraklion, Voutes, Greece.
Eur J Clin Invest. 2010 Nov;40(11):968-75. doi: 10.1111/j.1365-2362.2010.02348.x. Epub 2010 Aug 19.
C-reactive protein (CRP) is recognized as a potential factor implicated in atherogenesis and associated cardiovascular morbidity. The aim of our study was to assess the CRP evolution during 1-year follow-up period in obstructive sleep apnoea (OSA) patients under CPAP treatment.
Five hundred and twenty-eight patients with newly diagnosed moderate to severe OSA were included. CRP was assessed before CPAP initiation and at the 3rd, 6th and 12th month of the follow-up period. Patients were divided into good and poor CPAP compliance groups.
A significant reduction in CRP levels was observed after CPAP therapy (0·74±0·62mgdL(-1) vs. 0·31±0·29mgdL(-1) , P<0·001) in the whole patient group. The evolution of CRP values showed a gradual decrease at 3months with a steep decline at 6months, reaching a plateau after this time point. When the patients were divided into those with good and poor compliance with CPAP therapy, the above CRP evolution pattern was observed only in the former group.
Good CPAP compliance results in a significant CRP reduction. To achieve the best positive impact on cardiovascular morbidity and mortality, a time period of at least 6months of CPAP use is required.
C 反应蛋白（CRP）被认为是动脉粥样硬化形成和相关心血管疾病发病机制中的一个潜在因素。我们的研究目的是评估阻塞性睡眠呼吸暂停（OSA）患者接受 CPAP 治疗 1 年期间 CRP 的变化。
共纳入 528 例新诊断为中重度 OSA 的患者。在 CPAP 治疗开始前和随访第 3、6、12 个月评估 CRP。将患者分为 CPAP 依从性良好和不良组。
在整个患者组中，CPAP 治疗后 CRP 水平显著降低（0.74±0.62mg/dL 与 0.31±0.29mg/dL，P<0.001）。CRP 值的变化趋势是在 3 个月时逐渐下降，6 个月时急剧下降，此后达到平台期。当将患者分为 CPAP 治疗依从性良好和不良组时，仅在前一组中观察到上述 CRP 变化模式。
CPAP 治疗依从性好可显著降低 CRP。为了对心血管发病率和死亡率产生最佳的积极影响，CPAP 治疗需要至少 6 个月的时间。
